The 21st century has, in many ways, been shaped by the rapid advancements in technology and medicine. As we edge into the next decade, one of the most profound shifts on the horizon concerns the CPG and “Big Food” industries. Their challenge? Adapting to the changing consumer behaviors driven by the rising adoption of GLP-1 class pharmaceuticals.
本会员简报专为以下人士设计
执行委员为了方便加入，您可以点击下面的链接，获取数百份报告、我们的 DTC 权力清单和其他工具，帮助您做出高水平的决策。
在此加入
